Amgen Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value and what the price assumes
Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.
Starts at revenue growth over the last three years, 11.8% a year (statements).
US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).
Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.
Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.
Debt less cash at the end of FY2025 (statements); negative means more cash than debt.
What today's price assumes
A market value of $249.2 B means free cash flow growing 14.8% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.
Revenue grew 11.8% a year over the last three years.
Against the market value, for other rates
Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.
| Discount rate ↓ / growth → | 6.77% | 9.27% | 11.77% | 14.27% | 16.77% |
|---|---|---|---|---|---|
| 7.92% | -27% | -7% | +17% | +46% | +80% |
| 8.92% | -42% | -26% | -7% | +16% | +44% |
| 9.92% | -53% | -40% | -24% | -5% | +18% |
| 10.92% | -61% | -50% | -37% | -21% | -1% |
| 11.92% | -68% | -58% | -47% | -33% | -17% |
On one scale
Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.
Your own DCF model
A full discounted-cash-flow model of Amgen Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Pharmaceutical
Multiples of its companies with a market value at most 60 days old, times Amgen Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | Amgen Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| P/E | 18.4× / 38.7× / 53.5× | 26.5× | net income $7.7 B | $141.5 B to $412.4 B | 53 |
| Price to sales | 1.5× / 3.5× / 6.7× | 6.4× | revenue $36.8 B | $55.9 B to $246.2 B | 68 |
| Price to book | 2.1× / 4.1× / 8.0× | 28.8× | book equity $8.7 B | $17.9 B to $69.0 B | 62 |
Against its own history
Amgen Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
P/E
28.5×Now above its median of 25.5×, in the top quarter of its range; range 17.1× to 40.7× over 30 months.
Price to sales
6.5×Now above its median of 5.0×, in the top quarter of its range; range 4.2× to 6.5× over 30 months.
Price to book
28.8×Now above its median of 25.9×, in the top quarter of its range; range 11.5× to 44.3× over 30 months.
As of Oct 30, 2026
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $36.8 B | $7.7 B | $10.0 B | $1.9 B | $8.1 B | $45.5 B | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $33.4 B | $4.1 B | $11.5 B | $1.1 B | $10.4 B | $48.1 B | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $28.2 B | $6.7 B | $8.5 B | $1.1 B | $7.4 B | $53.7 B | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $26.3 B | $6.6 B | $9.7 B | $936 M | $8.8 B | $31.3 B | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $26.0 B | $5.9 B | $9.3 B | $880 M | $8.4 B | $25.3 B | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $25.4 B | $7.3 B | $10.5 B | $608 M | $9.9 B | $26.7 B | SEC annual report (10-K, 20-F) |